27
7
8
3a
8
4f
16
c
f
19
1
49
2
8
8
28
11
1b
1d
18
79
34
1d
2 29
1d
25
34
Ronac Mamtani, MD, MSCE
8cAssociate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
26
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
2c
Office: 2156627606
34 Fax: (215) 349-8551
24
99
34 Fax: (215) 349-8551
24
Email:
ronac.mamtani@uphs.upenn.edu
12
ronac.mamtani@uphs.upenn.edu
13
Education:
21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
3
3
3
3
92
Permanent link21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
2 29
21
1e
1d
24
7
29
27
23
10c Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
161 Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.
15a Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis. J Manag Care Spec Pharm Sep 2025.
10b Chow RD, Mamtani R.: Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma. Clin Genitourin Cancer Aug 2025.
111 Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8(7): e2520726, Jul 2025.
f9 Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.: Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates. JAMA Netw Open 8(7): e2519524, Jul 2025.
120 Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R.: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J Natl Cancer Inst 117(6): 1276-1278, Jun 2025.
12a Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA.: Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol 11(6): 666-668, Jun 2025.
15c Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L.: Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis. Clin Genitourin Cancer 23(5): 102395, Jun 2025.
2c
7
1d
1f
Selected Publications
131 Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U.: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2. J Comp Eff Res Oct 2025.10c Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
161 Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.
15a Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis. J Manag Care Spec Pharm Sep 2025.
10b Chow RD, Mamtani R.: Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma. Clin Genitourin Cancer Aug 2025.
111 Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8(7): e2520726, Jul 2025.
f9 Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.: Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates. JAMA Netw Open 8(7): e2519524, Jul 2025.
120 Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R.: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J Natl Cancer Inst 117(6): 1276-1278, Jun 2025.
12a Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA.: Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol 11(6): 666-668, Jun 2025.
15c Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L.: Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis. Clin Genitourin Cancer 23(5): 102395, Jun 2025.
2c